Hims & Hers Health Inc [HIMS] stock prices are up 12.04% to $14.70 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The HIMS shares have gain 43.41% over the last week, with a monthly amount glided 64.98%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results. In a post published today on Yahoo Finance, Revenue of $872.0 million, up 65% year-over-year in 2023.
From an analyst’s perspective:
Hims & Hers Health Inc [NYSE: HIMS] stock has seen the most recent analyst activity on February 28, 2024, when Imperial Capital upgraded its rating to a Outperform but kept the price target unchanged to $16 for it. Previously, Leerink Partners started tracking the stock with Market Perform rating on February 26, 2024, and set its price target to $10. On December 07, 2023, Imperial Capital initiated with a In-line rating and assigned a price target of $9 on the stock. TD Cowen started tracking the stock assigning a Outperform rating and suggested a price target of $11 on July 28, 2023. Robert W. Baird initiated its recommendation with a Neutral and recommended $10 as its price target on April 11, 2023. Jefferies upgraded its rating to Buy for this stock on February 09, 2023, and upped its price target to $11. In a note dated November 08, 2022, SVB Leerink upgraded an Outperform rating on this stock but restated the target price of $5.
The stock price of Hims & Hers Health Inc [HIMS] has been fluctuating between $5.65 and $13.91 over the past year. Currently, Wall Street analysts expect the stock to reach $6.33 within the next 12 months. Hims & Hers Health Inc [NYSE: HIMS] shares were valued at $14.70 at the most recent close of the market. An investor can expect a potential drop of -56.94% based on the average HIMS price forecast.
Analyzing the HIMS fundamentals
The Hims & Hers Health Inc [NYSE:HIMS] reported sales of 872.00M for trailing twelve months, representing a surge of 47.50%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -0.03%, Pretax Profit Margin comes in at -0.02%, and Net Profit Margin reading is -0.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.07 and Total Capital is -0.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.73 points at the first support level, and at 12.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.28, and for the 2nd resistance point, it is at 15.86.
Hims & Hers Health Inc [HIMS] reported earnings per share of $0.01 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.02/share, meaning a difference of $0.03 and a surprise factor of 150.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.04 per share as compared to estimates of -$0.03 per share, a difference of -$0.01 representing a surprise of -33.30%.
Ratios To Look Out For
It’s worth pointing out that Hims & Hers Health Inc [NYSE:HIMS]’s Current Ratio is 3.00. On the other hand, the Quick Ratio is 2.74, and the Cash Ratio is 1.09. Considering the valuation of this stock, the price to sales ratio is 3.57, the price to book ratio is 9.12.
Transactions by insiders
Recent insider trading involved Dudum Andrew, Chief Executive Officer, that happened on Mar 01 when 0.24 million shares were sold. Chief Executive Officer, Dudum Andrew completed a deal on Mar 01 to sell 0.14 million shares. Meanwhile, Chief Executive Officer Dudum Andrew sold 0.58 million shares on Feb 29.
